Single and Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of NM-101
Status:
Not yet recruiting
Trial end date:
2024-06-14
Target enrollment:
Participant gender:
Summary
This is a Phase I, double-blind, randomised, two-part, single-ascending dose (Part 1) and
multiple-ascending dose (Part 2) study of NM-101 in healthy males and healthy females of
non-childbearing potential